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IMAGES IN CARDIOLOGY  
 
Catheter Ablation of Incessant Ventricular 
Tachycardia in a Patient With Coronary Artery 
Disease 
Konstantinos P. Letsas, MD, Michael Efremidis, MD, 
Antonios Sideris, MD 
Second Department of Cardiology, Evagelismos 
General Hospital of Athens, Greece. 
 
A 67-year-old male with known coronary artery 
disease was referred to our hospital for catheter ablation 
of incessant ventricular tachycardia (VT). Transthoracic 
echocardiography revealed severe wall motion 
abnormalities of the left ventricle along with an apical 
aneurysm. Left ventricular voltage mapping showed a 
region with low voltage (<1.5 mV) at the left ventricular 
apex. Propagation mapping revealed a macro-reentry 
circuit around the apical aneurysm. Mid-diastolic 
potentials were recorded during the VT (Fig. 1, left panel, 
arrows), while entrainment mapping was excellent. The 
first radiofrequency energy application terminated the 
tachycardia. A circumferential lesion around the 
aneurysm was finally performed (Fig. 1, right panel, red 
dots). Ventricular tachycardia became non-inducible, and 






Figure 1. Surface ECG and intracardiac electrograms are 
depicted on the left panel and electroanatomical mapping 
on the right panel (see text for discussion) 
 
 
Cardiology News /Recent Literature Review 
 
Ector Anninos, MD, Spyridon Koulouris, MD, Antonis 
S. Manolis, MD 
 
The TCT Annual Conference will be held in San 
Francisco 7-11/11/2011  
 
The AHA Annual Scientific Sessions are scheduled for 
12-16/11/2011 in Orlando 
 
The next ACC Annual Meeting is slated for 24-
27/3/2012 in Chicago 
 
The Athens Cardiology Update 2012 is slated for April 
5-7, 2012 
 
The HRS 33rd Annual Meeting will be held in Boston, 9-
12/5/2012 
 
The next ESC Annual Congress will be held in Munich, 
25-29/8/2012 
 
Incidence and Predictors of ICD Therapy in Patients 
With Arrhythmogenic Right Ventricular Dysplasia/ 
Cardiomyopathy (ARVC) Undergoing ICD 
Implantation for Primary Prevention 
Eighty-four patients with definite or probable ARVC 
underwent ICD implantation for primary prevention. 
After a follow-up of 4.7 ± 3.4 years, appropriate ICD 
therapy was delivered in 40 patients (48%). Predictors of 
such an intervention were proband status (p < 0.001), 
inducibility at electrophysiologic study (p = 0.005), 
presence of nonsustained ventricular tachycardia (p < 
0.001), and Holter premature ventricular complex count 
>1,000/24 h (p = 0.024). In multivariate analysis, 
inducibility at electrophysiologic study and nonsustained 
ventricular tachycardia remained significant predictors. 
The number of these risk factors correlates with the 
incidence of ICD activation with the 5-year survival free 
of appropriate ICD therapy for patients with 1, 2, 3, and 4 
risk factors being 100%, 83%, 21%, and 15%, 
respectively (Bhonsale A et al, J Am Coll Cardiol 2011; 
58:1485-1496).  
 
Exclusion of the Left Atrial Appendage with a Novel 
Device: Early Results of a Multicenter Trial 
Seventy patients with atrial fibrillation or a CHADS2 
score greater than 2 undergoing elective cardiac surgery 
were eligible for concomitant AtriClip device (35, 40, 45, 
and 50 mm) insertion. Safety was assessed at 30 days, 
and efficacy of left atrial appendage exclusion was 
assessed at operation (by transesophageal 
echocardiography) and at 3-month follow-up (by 
computed tomography angiography or transesophageal 
echocardiography). Intraprocedural success reached 
95.7% (67 of 70 patients). Although significant adverse 
events occurred in 34 of 70 patients (48.6%), none was 
related to the device and there was no perioperative 
mortality. At 3-month follow-up, 98.4% of the patients 
had successful left atrial appendage exclusion by 
computed tomography angiography or transesophageal 
echocardiography imaging (Ailawadi G et al, J Thorac 
Cardiovasc Surg 2011; 142:1002-1009).  
 
SCN5A Mutations Associate With Arrhythmic Dilated 
Cardiomyopathy and Commonly Localize to the 
Voltage-Sensing Mechanism 
In this study the role of the cardiac sodium ion 
channel SCN5A in the etiology of dilated 
cardiomyopathy (DCM) was examined. To achieve this, 
DNA samples from 338 individuals among 289 DCM 
families were screened for SCN5A mutations by 
sequence analysis. The authors identified 5 missense 
SCN5A mutations representing the 1.7% of DCM 
families. Three of these mutations are novel (E446K, 
F1520L, and V1279I) and two are already known ones 
(D1275N and R222Q). In the majority of the cases the 
mutation was located to the highly conserved 
homologous S3 and S4 transmembrane segments, 
suggesting the disruption of the voltage-sensing 
mechanism of this sodium channel as the underlying 
mechanism leading to DCM. Most of the SCN5A 
mutation carriers manifested supraventricular arrhythmia 
(13/15), sick sinus syndrome (5/15) atrial fibrillation 
(9/15), ventricular tachycardia (5/15), and conduction 
disease (9/15) (McNair WP et al, J Am Coll Cardiol 
2011;57: 2160-2168.) 
 
